A CASE OF POLY-INFECTION WITH cUTI AND GRADE III BED SORE IN TYPE II DIABETES TREATED WITH NEW ANTIBIOTIC ADJUVANT ENTITY: A CASE REPORT
Critically ill patients with diabetes are commonly associated with urinary tract infection and high-risk of bed sores or pressure ulcers. We report a case
of 72 years male patient, a known case of meningoencephalitis, treated 1 month back. He arrived to our emergency department, with chief complaints
of fever and increased drowsiness since 10-12 days. Based on the initial examination, the patient was empirically managed with intravenous
meropenem 1 g every 8 hrs. However, due to patient poor clinical response antibiotic therapy was switched to Elores 1.5 g B.D dose with 90 minutes
infusion. The patient received Elores therapy for 7 days, based on lab reports and general condition, he was put on oral antibiotics and shifted to ward.
On the 5
day of post ward transfer, the patient developed mild pleural effusion with mild hypokinesis, he was again shifted to Medical Intensive Care
Unit. Cardiology consultation was sought and was managed. In view of suspected hospital-acquired pneumonia, prophylactic treatment of Elores 1.5 g
B.D was continued for 5 days. The patient responded to the treatment well, was stable and discharged with follow-up advice.
Keywords: Antibiotic adjuvant entity, Complicated urinary tract infections, Elores, Poly-infection.
bacteriuria and urinary tract infections. West London Med J
2. Janifer J, Geethalakshmi S, Satyavani K, Viswanathan V. Prevalence of
lower urinary tract infection in South Indian type 2 diabetic subjects.
Indian J Nephrol 2009;19(3):107-11.
3. Tayyib N, Coyer F, Lewis P. Pressure ulcers in the adult intensive care
unit: A literature review of patient risk factors and risk assessment
scales. J Nurs Educ Pract 2013;3(11):28-42.
4. Frank C, Bayoumi I, Westendorp C. Approach to infected skin ulcers.
Can Fam Physician 2005;51(10):1352-9.
Asian J Pharm Clin Res, Vol 9, Issue 1, 2016, 7-9
5. Kirketerp-Moller K, Zulkowski K, James G. Chronic wound
colonization, infection, and biofilms. Biofilm Infect 2011;11-24 .
6. Chaudhary M, Payasi A. A randomized, open-label, prospective,
multicenter phase-III clinical trial of Elores in lower respiratory tract
and urinary tract infections. J Pharm Res 2013;6(4):409-14.
7. Chaudhary M, Payasi A. Antimicrobial susceptibility patterns and
molecular characterization of Klebsiella pneumoniae clinical isolates
from north Indian patients. Int J Med Med Sci 2013;46:1218-24.
8. Chaudhary M, Payasi A. Role of EDTA and CSE1034 in curli formation
and biofilm eradication of Klebsiella pneumoniae: A comparison with
other drugs. J Antibiot (Tokyo) 2012;65(12):631-3.
9. Sahu M, Sanjith S, Bhalekar P, Keny D. Waging war against extended
spectrum Beta lactamase and metallobetalactamase producing
pathogens- novel adjuvant antimicrobial agent cse1034- an extended
hope. J Clin Diagn Res 2014;8(6):DC20-3.
10. Chaudhary M, Payasi A. Clinical, microbial efficacy and tolerability
of Elores, a novel antibiotic adjuvant entity in ESBL producing
pathogens: Prospective randomized controlled clinical trial. J Pharm